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INTRODUCTION  
Development of controlled release transdermal dosage 
form is a complex process involving extensive research. 
Transdermal patches have been developed to improve 
clinical efficacy of the drug and to enhance patient 
compliance by delivering smaller amount of drug at a 
predetermined rate. This makes evaluation studies even 
more important in order to ensure their desired 
performance and reproducibility under the specified 
environmental conditions. These studies are predictive of 
transdermal dosage forms and can be classified into 
following types: 
I. Physico-chemical evaluation 
II. Evaluation of Adhesive 
III. In-vitro and Ex-vivo drug release evaluation 
IV. In-vivo drug release evaluation 
V. Skin irritation test  
VI. Other evaluation instrumental techniques 
VII. Accelerated stability studies 
 
I. Physico-chemical evaluation 
A. Drug- Polymer Interaction studies  
The drug and the excipients must be compatible with one 
another to produce a product that is stable. The 
interaction between drug and excipients affect the 
bioavailability and stability of the drug. If the excipients 
are new and have not been used in formulations 
containing the active substance, the compatibility studies 
play an important role in formulation development. 
Interaction studies were conducted on the medicated 
TDDS formulations by comparing them with the pure 
drug and placebo formulations on the basis of Thermal 
analysis (Differential Scanning Calorimetry), Fourier 
transform infrared spectroscopy (FTIR), ultra violet 
(UV) and chromatographic techniques by comparing 
their physicochemical properties like Assay, Melting 
point, Wave numbers, and Absorption maxima, RF value 
etc. 
Assay  
The patches were dissolved in the respective solvent and 
the drug content was determined by UV 
spectrophotometry 
1,2
.  
UV Analysis  
The medicated and blank formulations were filtered 
through Whatman filter paper no. 42 and scanned 
spectrophotometrically at the range of 200–400 nm 2.  
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ABSTRACT 
Designing and development of transdermal patches can be described as state of the art. The development of Transdermal drug 
delivery system is multidisciplinary activity that encompasses fundamental feasibility studies starting from the selection of 
drug molecule to the demonstration of sufficient drug flux in an ex vivo and in vivo model followed by fabrication of a drug 
delivery system that meets all the stringent needs that are specific to the drug molecule (physicochemical and stability factors), 
the patient (comfort and cosmetic appeal), the manufacturer (scale up and manufacturability) and most important the economy. 
The assessment of the performance of transdermal therapeutic devices designed for controlled drug release may result in a 
complex analytical issue and multidisciplinary studies focused on the evaluation of physicochemical, morphological and 
textural properties of the products may be required. This paper presents a review of transdermally applied formulations with 
emphasis on the evaluation of patches in a wide variety of evaluation parameters such as Physico-chemical evaluation, 
Adhesive evaluation, Skin irritation test, In-vitro, Ex-vivo, In-vivo techniques using animal models and human skin and 
Accelerated stability studies. 
Keywords: Transdermal patches, Physico-chemical evaluation, Adhesive evaluation, Skin irritation test, In-vitro, Ex-vivo and 
In-vivo techniques, Accelerated stability studies. 
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Figure 1: UV-Visible Spectrophotometer 
 
Figure 2: Typical UV-Visible Spectra 
Thin Layer Chromatography (TLC) 
Compatibility studies are carried out to assess any 
incompatibility between drug and polymers. The TLC 
plates having silica gel coating of 0.25 mm thickness 
were used after activating in an oven for one hour at 
120 
0
C. A spot of the standard solution was put 2 cm 
from the bottom. The sample solution was spotted 
2cms apart from one another and placed in TLC 
chamber, which was previously saturated with the 
solvent system. The solvent was allowed to rise at least 
3/4th of the plate and the distance travelled by solvent 
front was noted. After the migration of the solvent 
system, the plate was air dried and visualized in 
CAMAG UV TLC cabinet, whereas; iodine vapor 
were used as visualizing agent. The Rf value was 
calculated for the standard and sample solutions using 
the formula 
3
 
Rf  Value = Distance travelled by the solute from the 
origin/ Distance travelled by the solvent from the 
origin 
 
Figure 3: Thin Layer Chromatography 
Fourier Transform Infra-Red (FTIR)  
The FTIR absorption spectra of the pure, medicated 
and blank formulations were taken in the range of 400–
4000 cm
–1
using the potassium bromide disc method. 
IR spectroscopy is one of the important analytical 
techniques to determine the structure of a compound 
and predict the presence of certain functional groups 
which are observed at a definite frequency. A peak-by-
peak correlation is excellent evidence for identity 
4,5,6
.  
 
 
Figure 4: Fourier Transform Infrared 
Spectrophotometer 
Differential Scanning Calorimetry (DSC) 
The DSC of the pure drug and drug-polymer blend was 
studied at a scanning rate of 10
o
C/ min between 50 to 
300
o
C. The sample was hermetically sealed in an 
aluminum crucible. Nitrogen gas was purged at the rate 
of 10 ml/m for maintaining inert atmosphere 
4
. 
 
 
 
Figure 5: Differential Scanning Calorimeter 
 
B. Physical appearance:  
All the prepared patches were visually inspected for 
color, clarity, flexibility and smoothness 
7,8
. 
C. Thickness uniformity 
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The thickness of transdermal film is determined by 
travelling microscope, dial gauge, screw gauge or 
micrometer at different points of the film. The 
thickness was measured at six different places on each 
film and the average thickness of the film was taken as 
the thickness of the film 
9,10
. 
D. Uniformity of  weight 
A specified area (1 cm
2
) of patch is to be cut in 
different parts of the patch and is to be dried at 60°c 
for 4hrs before testing and Weight variation is studied 
by individually weighing 10 randomly selected patches 
and calculating the average weight. The individual 
weight should not deviate significantly from the 
average weight 
11,12
. 
E. Drug content determination 
An accurately weighed portion of patch is dissolved in 
100 ml of suitable solvent in which drug is soluble and 
then the solution is shaken continuously for 24 hrs in 
shaker incubator. Then the whole solution is sonicated 
for complete extraction of drug from the patch. After 
incubation and subsequent filtration, drug in solution is 
estimated against the reference solution consisting of 
placebo films (contains no drug) with the suitable 
method (UV or HPLC technique) 
13,14
. 
F. Surface pH 
Transdermal films were allowed to swell for 2 h at 
37˚C on the surface of an agar plate, prepared by 
dissolving 2% (w/v) agar in worm isotonic phosphate 
buffer of pH 5.5 under stirring and then pouring the 
solution into a Petri dish till gelling at room 
temperature. The surface pH was measured by means 
of a pH paper placed on the surface of the swollen 
patch. After 90 s the color developed. The mean of six 
reading was recorded and tabulated 
15
. 
G. Folding endurance 
Evaluation of folding endurance involves determining 
the folding capacity of the films subjected to frequent 
extreme conditions of folding. Folding endurance is 
determined by repeatedly folding the film at the same 
place until it break; the number of times the films 
could be folded at the same place without breaking is 
folding endurance value 
16
. 
 
Figure 6: Folding Endurance tester 
H. Tensile Strength 
Tensile strength of the film was determined with 
Universal Strength Testing Machine (Hounsfield, 
Slinfold, Horsham, U.K).The sensitivity of the 
machine was 1 g. It consisted of two load cell grips. 
The lower one was fixed and upper one was movable. 
The test film of size (4×1cm
2
) was fixed between these 
cell grips and force was gradually applied till the film 
broke. The tensile strength of the patch was taken 
directly from the dial reading in kg/cm
2
. Tensile 
strength is expressed as follows 
17,18,72
: 
 
 
Figure 7: Tensile Strength Testing Machine 
 
I. Percentage elongation break test  
The percentage elongation break is determined by 
noting the length just before the break point, the 
percentage elongation can be determined from the 
below mentioned formula 
19
: 
Elongation % =L1-L2/L2×100 
Where, L1is the final length of each strip and L2 is the 
initial length of each strip. 
J. Flatness 
A transdermal patch should possess a smooth surface 
and should not constrict with time. This can be 
demonstrated with flatness study. For flatness 
determination, one strip is cut from the centre and two 
from each side of patches. The length of each strip is 
measured and variation in length is measured by 
determining percent constriction.  0% constriction is 
equivalent to 100 % flatness 
20,75
. 
 
L2 = Final length of each strip 
L1 = Initial length of each strip 
K. Percentage moisture absorption 
Initial weight of the patch was taken and noted, then 
weighed patch are kept in desiccators at room 
temperature for 24 h. These are then taken out and 
exposed to 75% relative humidity using saturated 
solution of sodium chloride in desiccators until a 
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constant weight is achieved. Final weight of the patch 
was calculated and percentage moisture uptake is 
calculated as given below 
21
.  
        Final wejght – Initial weight 
% Moisture uptake =  -------------------------------- ×100 
           Initial weight 
 Percentage moisture loss 
The prepared patch are weighed individually and kept 
in a desiccators containing fused calcium chloride at 
room temperature for 24 h. The patch is weighed again 
after a specified interval until they show a constant 
weight. The percent moisture content is calculated 
using following formula 
22, 23,24,65
: 
% Moisture Content = Initial wejght – Final weight 
                              -------------------------------- × 100 
           Final weight 
L. Water vapor Transmission Rate 
 For this study, vials of equal diameter were used as 
transmission cells. These cells were washed thoroughly 
and dried in an oven, about 1 g of fused calcium 
chloride was taken in cells and the polymeric patches 
measuring 1 cm
2 
area were fixed over the brim with the 
help of an adhesive. The cells were weighed accurately 
and initial weight was recorded, and then kept in a 
closed desiccator containing saturated solution of 
potassium chloride to maintain 63 % RH. The cells 
were taken out and weighed after 72 h. The amount 
and rate of water vapor transmitted was calculated by 
the difference in weight using the formula 
25,26,70
: 
WVT rate = WL/S 
Where, W is the water vapor transmitted in grams, L is 
the thickness of the film in cm, and  S  is  the exposed 
surface area in square cm. 
M. Swelling Studies  
Weight and area increase due to swelling were 
measured.  
Weight increase due to Swelling 
The drug-loaded patch of size 1 x 1 cm
2 
was weighed 
on a pre-weighed cover slip. It was kept in a petridish 
and 50 ml of phosphate buffer (pH 7.4) solution was 
added. After every five min, the cover slip was 
removed, wiped with tissue paper, and weighed upto 
30 min. The difference in the weights gives the weight 
increase due to absorption of water and swelling of 
patch 
27, 28
.  
Area increase due to Swelling 
 A drug loaded patch of size 1x1 cm
2 
was cut and 
placed in a petridish containing 50 ml of phosphate 
buffer (pH 7.4) solution. A graph paper was placed 
beneath the petridish and was clearly visible, which 
facilitated the measurement of increase in the area. An 
increase in the length and breadth of the patch was 
noted at five min intervals for 60 min and the area was 
calculated. The percent swelling, %S was calculated 
using the following equation; 
 
Where Xt is the weight or area of the swollen patch 
after time t and Xo is the original patch weight or area 
at zero time. 
N. Bursting strength 
A test for measuring the resistance of a film to bursting 
and reported in kilo-Pascal or pounds per square inch 
or kg/cm
2
. The burst strength of all the patches was 
evaluated by using standard bursting strength tester 
29, 
30
. 
 
Figure 8: Bursting Strength Tester 
 
II. Evaluation of Adhesive 
 Pressure sensitive adhesives are evaluated for the 
following properties 
27-31,64,68,73,76,84,86
. 
A. Peel adhesion properties 
Peel adhesion is the required to remove an adhesion 
coating from a test substrate. The important in 
transdermal devices because the adhesive should 
provide adequate contact of the device with the skin 
and should not damage the skin on removal. Peel 
adhesion properties are affected by the molecular 
weight of the adhesive polymer, the type & amount of 
additives and polymer composition. It is tested by 
measuring the force required to pull a single coated 
tape applied to a substrate at 180
o
 angle.  
 
Figure 9: Peel adhesion test for adhesive evaluation 
 
B. Shear strength properties  
Shear strength is the measurement of the cohesive 
strength of an adhesive polymer. Adequate cohesive 
strength of a device will mean that the device will not 
slip on application and will leave no residue on 
removal. It is determined by measuring the time it 
takes to pull on adhesive coated tape off a stainless 
steel plate when a specified weight is hung from the 
tape which pulls the tape in a direction parallel to the 
plate. 
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Figure 10: Shear strength test for adhesive 
evaluation 
C. Track properties  
Track is the ability of a polymer to adhere to a 
substrate with little contact pressure.  
It is important in transdermal devices which are 
applied with finger pressure. Track is dependent on the 
molecular weight and composition of polymer as well 
as the use of tackifing resins in the polymer. Tests for 
tack include:  
i)  Thumb tack test 
This is a subjective test in which evaluation in done by 
pressing the thumbs briefly into the adhesive 
experience is required for using this test. 
ii)  Rolling ball tack test  
This test involves measurement of the distances that a 
stainless ball travels along an upward-facing adhesive. 
The less tacky the adhesive the farther the ball will 
travel.  
 
Figure 11: Rolling ball tack test for adhesive 
evaluation 
iii)  Quick stick (or peel-tack) test 
The peel force required to break the bond between an 
adhesive and substract is measured bnuy pulling the 
tape away form the substract at 90
o s
at a speed of 12 
inch/min. 
 
Figure 12: Quick stick test for adhesive evaluation 
iv) Probe tack test 
The force required to pull a probe away from on 
adhesive at a fixed rate is recorded at tack. 
 
Figure 13: Probe tack test for adhesive evaluation 
 
III. In-vitro and Ex-vivo drug release evaluation 
A. In vitro drug release studies 
The release rate determination is one of the most 
important studies to be conducted for all controlled 
release delivery systems. The dissolution studies of 
patches are crucial because one needs to maintain the 
drug concentration on the surface of the stratum 
corneum consistently and keep it substantially higher 
than the drug concentration in the body, to achieve a 
constant rate of drug permeation.
[63,66,67]
 The following 
apparatus are used for in-vitro drug release studies for 
transdermal therapeutic systems:- 
a. The Paddle over Disc (USP apparatus V) 
b. The Cylinder modified USP Basket (USP apparatus 
VI) 
c. The Reciprocating disc (USP apparatus VII)   
 
Figure 14: Different Dissolution Apparatus as per 
USP 
a. The Paddle over Disc (USP apparatus V)  
The paddle over disc method (USP apparatus V) can 
be employed for assessment of the release of the drug 
from the prepared patches. This method is identical to 
the USP paddle dissolution apparatus, except that the 
transdermal system is attached to a disc or cell resting 
at the bottom of the vessel. Dry films of known 
thickness were cut into definite shape, weighed, and 
fixed over a glass plate with an adhesive. The glass 
plate was then placed in a 500 ml of the dissolution 
medium or phosphate buffer (pH 7.4), and the 
apparatus was equilibrated to 32 ± 0.5°C. The paddle 
was then set at a distance of 2.5 cm from the glass 
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plate and operated at a speed of 50 rpm. Samples (5 ml 
aliquots) can be withdrawn at appropriate time 
intervals up to 24 h and analyzed by UV 
spectrophotometer or HPLC. The experiment was 
performed in triplicate and the mean value calculated 
[32]
. 
 
Figure 15: Paddle over Disc (USP apparatus V) 
b. The Cylinder modified USP Basket (USP 
apparatus VI)  
This method is similar to the USP basket type 
dissolution apparatus, except to replace the basket  and  
shaft  with a  stainless  steel  cylinder  stirring  
element. immersed in medium at 32 ±0.5°C 
[33]
.  
 
Fig 16: Cylinder modified USP Basket (USP 
apparatus VI) 
c. The reciprocating Disc/Holder apparatus (USP 
apparatus VII)  
Originally  introduced  in  the  USP  as  a  small-
volume  option  for small  transdermal  patches,  the  
reciprocating  disk  apparatus  was later  renamed  the  
reciprocating  holder  apparatus  with the  adoption of 
four additional holders for transdermal systems, 
osmotic pumps, and other low-dose delivery systems. 
In this method patches attached to holders are 
oscillated in small volumes of medium, allowing the 
apparatus to be useful for systems delivering low 
concentration of drug 
[34]
.  
 
Fig 17: Reciprocating disc sample holder 
B. Ex vivo skin permeation studies (In vitro skin 
permeation studies) 
The amount of drug available for absorption to the 
systemic pool is greatly dependent on drug released 
from the polymeric transdermal films. The drug 
reached at skin surface is then passed to the dermal 
microcirculation by penetration through cells of 
epidermis, between the cells of epidermis through skin 
appendages. 
Skin model used for transdermal drug delivery 
system 
Various skin models used by various researchers are 
given in Figure. Though there is no rule regarding to 
selection of the skin model. But generally researchers 
start with artificial membrane, then in vitro animal 
skin, then in vitro human skin (cadaver skin), then in 
vivo animal skin, then finally in vivo human skin 
34,35,69,71,74
. 
 
Fig 18: Various skin models for transdermal drug delivery system 
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Animal Models 
Ex vivo penetration and permeation are routinely 
performed to study percutaneous absorption and 
transdermal permeation characteristics of drugs and other 
chemicals. These ex vivo studies allow the determination 
of drug concentration in the skin (penetration) and rate of 
transfer across the skin (permeation). Ex vivo 
experiments are easy to perform and the simplicity of 
methodology allows flexibility in adapting the model in 
addressing different aspects involved in preliminary or 
feasibility studies in the development of skin/transdermal 
drug delivery systems. It would be advantageous to use 
human cadaver skin for in vitro permeation studies but, 
in practice, for most investigators, human cadaver skin is 
not readily available. Thus animal skin is frequently used 
for in vitro studies. Weanling pig skin (skin from a pig 
that has recently been weaned) is recognized as the 
closest alternative to human cadaver skin in its 
permeability and lipid composition.  
An animal skin membrane that is sufficiently similar or 
close to human skin is needed to substitute human skin in 
ex vivo penetration and permeation, and topical 
bioavailability studies. Human skin is difficult to obtain 
and uniformity is difficult to maintain, since most of 
human skin comes from cadavers whose sex, age and 
genetic history are uncontrolled. Where as, animal skin is 
easier to obtain and is more uniform. Humans and 
animals have wide differences in the number of 
appendageal openings per unit area thickness of skin, 
structure and porosity of skin, and these factors clearly 
affect the percutaneous absorption of drugs. Only the 
progress in in vitro methodology with an appropriate 
animal model can resolve these limitations.  
It would be a simple mathematical exercise to predict the 
skin permeability in humans from animal experiments. If 
there is constant ratio between skin permeability in 
human to animal, independent of the drug under study. If 
correlation can be established for drugs with different 
physicochemical properties, experiments using 
appropriate animal skin will be more reliable in the 
developmental stage of skin/transdermal drug delivery 
systems.  
It appears that hairless guinea pig and Brattleboro rat are 
to be good animal models for skin/ transdermal drug 
delivery systems, where as snake appears not to be a 
good model to evaluate permeation of drugs across skin. 
In reviewing the studies comparing transdermal 
absorption of drugs between animals and humans, care 
must be taken to ascertain the influences of methodology 
and model might have on the data, and utmost care must 
be taken to avoid any misinterpretation or wrong 
conclusions 
35,78-80 
.  
According to the literature available no consensus is 
available regarding animal models which truly reflect 
human skin. 
Skin Preparation 
Respective skin was excised from the animals. The 
subcutaneous fat, tissue, blood vessel and epidermal 
hairs were carefully removed. The skin with free of 
obvious holes or defects were cleaned with normal saline 
and finally with sterile water. Then it was soaked in 
phosphate buffer pH 7.4 solutions for 12 hrs refrigeration 
before use.  T o perform ex-vivo skin permeation, the 
skin was thawed at room temp and used 
35,36
. 
Apparatus for Ex vivo skin permeation studies 
Ex vivo skin permeation methods are used in laboratories 
all over the world with the intention to assess the 
penetration characteristics of specific substances. A 
range of different designs have been developed with the 
general aim to measure the penetration of agents through 
the skin membrane into a fluid reservoir 
77,81
.  
a. Static Franz diffusion cell 
In 1975 Franz developed a static diffusion cell which is 
now one of the most commonly used in vitro systems in 
the research of skin penetration. The system has a simple 
design and is inexpensive to use. Human as well as 
animal skin can be mounted on the metal grid which 
divides the donor chamber and the receptor chamber. 
The skin is set placing the dermis in contact with the 
receptor fluid below. The skin can be either full-
thickness or split-thickness skin.  The receptor 
compartment has a volume of 5 -12ml and effective 
surface area of 1-5 cm
2
. The diffusion buffer is 
continuously stirred at 600rpm by a magnetic bar. The 
receptor chamber of the cell is placed in circulation water 
in a water bath with a temperature of 37 ºC keeping the 
temperature at the skin surface at 32° C to imitate a real 
life skin condition as much as possible. The receptor 
fluid is kept homogenous in concentration and in 
temperature by a magnetic stirring bar. The fluid in the 
receptor chamber is manually sampled at predefined time 
intervals 
38
. 
 
 
Figure 19: Static Franz diffusion cell 
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a. Horizontal /Side-by-side diffusion cell 
This has been widely used for the evaluation of drug 
permeation across skin. The cell is divided in receptor 
and donor compartments with a low solution volume 
(3.5ml) for each compartment and a small membrane 
area (0.64cm
2
). They are continuously stirred by matched 
set of star-head magnets, which are rotated at a speed of 
600rpm. The system is controlled by thermostated water 
through a water jacket surrounding the two 
compartments 
39
. 
 
Figure 20: Horizontal /Side-by-side diffusion cell 
 
b. Flow-through Franz diffusion cell 
Flow through diffusion cells have the advantage that they 
can be used when the drug has lower solubility in the 
receptor compartment. This cell can be fully automated 
and connected directly to HPLC. They have large 
capacity donor chamber to allow appropriate loading of 
the applied compound and a low volume (0.3ml) 
receiving chamber that ensures rapid removal of 
penetrant at relatively low pumping rates. 
The receptor fluid is in the flow-through cells 
continuously replaced and collected every hour to imitate 
an in vivo situation where the blood circulation removes 
the transdermal penetration substances. This has an 
additional benefit when dealing with substances with low 
solubility in the receptor medium and the sink conditions 
are maximized as the fluid is continually replaced. The 
flow-through system provides an environment similar to 
real physiological conditions by the continuous 
replacement of receptor fluid resembling the systemic 
uptake of the drugs/chemicals in the blood vessels 
40,41
.  
 
Figure 21: Flow-through Franz diffusion cell 
IV. In-Vivo Evaluation 
In vivo technique is based on a physiologically and 
metabolically intact system. There are two kinds of in 
vivo studies 
82, 83, 85, 87
:  
1) Animal studies  
2) Human studies 
1) Animal studies  
In vivo animal models are preferred because 
considerable time and resources are required to carry out 
studies in humans. Some of the species that have been 
used for in vivo testing include; mouse, rat, guinea pig, 
rabbit, hairless mouse, hairless rat, hair less dog, cat, 
dog, pig, swine,  horse, goat, squirrel, monkey, rhesus 
monkey, chimpanzee, etc. Various experiments have 
been carried out to determine which of the animal 
models provide the best prediction of the behavior of the 
device, being tested, in humans. The most frequently 
used animal is the rat even though it is well known that 
rat studies generally overestimate human skin absorption. 
Other animals like Rhesus monkey is one of the most 
reliable models for in vivo evaluation and demonstrate a 
better agreement with human absorption, but the costs of 
these are considerably higher. Various experiments 
conducted lead us to a conclusion that hairless animals 
are preferred over hairy animals in both in vitro and in 
vivo experiments.  
A group of researchers has investigated percutaneous 
absorption and found a decreasing order of permeation, 
thus, rabbit>rat> swine>man. Nevertheless, other studies 
have shown that that data from these lower animals are 
comparable to that of man even though such studies in 
animals either in vivo or in vitro can only be useful 
approximations of activity in man 
42-44
. 
2) Human studies 
The last phase in the transdermal absorption studies of a 
drug is the in vivo clinical studies on humans. The 
standard principals described were application of the test 
substance to the skin in proper form and time, taking 
samples of different body fluids, excreta or tissue at 
specific intervals, and quantifying the test substance in 
the samples or the metabolite in the samples by an 
appropriately sensitive analytical method 
45
. 
 The conduct of in vivo studies in volunteers is closely 
regulated. The study protocol should be approved by an 
ethical committee and the subjects have to give written 
informed consent. 
Several methods are available for in vivo percutaneous 
studies. These are discussed below: 
a. Traditional in vivo technique (Plasma/ excreta 
measurement) 
The test substance is applied to the skin of healthy 
humans and blood and/or urine is collected and analysed. 
The amount of test substance measured in the blood 
and/or urine gives a good indication of the amount of 
substance absorbed through the skin into the systemic 
circulation. In vivo studies, the substance is applied 
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during a certain period to a specified area of the skin site 
of volunteers/animal. The percutaneous absorption can 
be assessed by analyzing the parent chemical and/or its 
metabolite(s) in the skin layers or in biological media 
such as plasma, urine or exhaled air. The amount of a 
chemical measured after dermal exposure is compared to 
that after a reference exposure with a known dose via, for 
example, intravenous administration or inhalation. 
This in vivo technique has been used before all other 
techniques were ever considered and is still used where 
there is no adverse risk to the volunteers participating. 
Often the test of a substance is intended to disclose 
different unknown characteristics of the substance 
signifying that the knowledge of the substance is limited 
or incomplete and therefore the risk assessment may not 
be completely explained. This gives rise to ethical 
concern and limits the use of healthy volunteers 
46-48
. 
b. Microdialysis 
Microdialysis is a technique used in the clinic as well as 
in research for sampling of endogenous and exogenous 
substances in the extracellular space in the living tissue 
e.g. the skin. Microdialysis is so far the only technique 
that provides information from the extracellular space, 
and it is therefore of great importance in the investigation 
of pharmacological and biochemical procedures in these 
tissues. Several results in drug discovery and 
development are established by measuring serum 
concentrations of different molecules, even though most 
drugs exert their effects in the tissues and not in the 
blood stream. Thus, data on pharmacokinetics at the 
target site are important, just as determination of 
pharmacodynamic effects in relation to tissue drug 
concentrations in the target tissue is a more precise 
approach to describe exposure effects.  
 
Figure 22: Microdialysis 
Microdialysis is currently the most essential tool to 
estimate active drug profiles at the target site and for 
providing pharmacokinetic and pharmacodynamic 
information. Principals in microdialysis are to imitate the 
function of a small blood vessel in the dermis. A test 
substance applied to the skin will penetrate the skin 
surface to the dermis where the artificial blood 
vessel/probe is placed. The probes consist of a semi-
permeable structure which allows molecules to pass into 
the perfusate inside the probe by passive diffuse. The 
molecules follow a concentration gradient across the 
probe membrane as the perfusate inside the probe passes 
through, driven at a constant and very accurate pace by a 
pump. A partial equilibration of molecules across the 
membrane occurs. The perfusate – now called the 
dialysate - leaves the probe, holds the test substance and 
is collected in small vials for analysis. This technique has 
been used in human volunteers as well as in animals 
49, 50
. 
c. Tape stripping method 
Tape stripping is a well known in vivo technique but can 
also be used in vitro. A test substance (often 
radioactively labelled) is allowed to penetrate the skin at 
a predetermined area for a certain time period. 
Afterwards the skin is gently washed to remove 
remaining unabsorbed test substance on top of the skin. 
The method then involves sequentially removing of 
microscopic layers of the exposed stratum corneum by 
repeated application and removal of adhesive tape. The 
amounts of recovered substance in these shedded cells 
attached to the tape are then analyzed using an 
appropriate analytical method. It has been reported that 
the amount of the chemical in these skin layers gave 
good estimate of the total amount of the chemical 
absorbed into the systemic circulation. The method is 
inexpensive, uncomplicated and a minimally invasive 
method given that only dead cells (corneocytes) 
embedded in their lipid matrix are removed. Tape 
stripping is a particularly helpful technique to assess the 
local bioavailability of drugs whose target site is the 
stratum corneum itself, like e.g. antiseptics, antifungal 
drugs 
51,52
. 
 
Figure 23: Tape stripping method 
 
V. Primary Skin irritation study 
The major cutaneous toxicological reaction results from 
direct toxic injury to cell membrane, cytoplasm or nuclei. 
This is generally manifested (to show, clearly especially 
a feeling) by inflammation and itching and can occurs 
from the drug, vehicle or absorption enhancer. 
Reversible inflammatory changes occurs due to 
interaction of chemicals with the sensory receptors in the 
skin at the site of application. The albino rabbit is the 
preferred animal species when testing for skin irritation 
because of its high skin sensitivity and light skin, on 
which even slight skin irritant effects of a substance 
usually can be detected. In general, substances or 
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products are tested for skin irritation using a test design 
first proposed by Draize et al. in 1944, which based on 
scoring method. Scores as assigned from 0 to 4 based on 
the severity of erythema or oedema formation. 
The skin irritation test was performed on healthy albino 
rabbit weighing 1.5 to 2.0 kg and 24 months of age. The 
animals were singly housed in suspended stainless steel 
caging with mesh floors in the animal unit under 
controlled temperature (27 ± 2°C) with 30 - 70 % 
relative humidity and 12 hours light/dark cycle. They 
were fed a standard laboratory diet and filtered tap water 
was provided ad libitum. A minimum of 7 days 
acclimatization was allowed before the commencement 
of the study. The animals were divided in 4 groups, 6 
animals per group. The dorsal surfaces (50 cm
2
) of the 
rabbits were shaved carefully avoiding peripheral 
damage. The skin was cleaned with 75% ethanol. 
Representative patches were placed on the skin and held 
in place with an adhesive tape. On the previous day of 
the experiment, the hair on the back side area of rat was 
removed. The animals of group I were served as control 
without any treatment. Transdermal systems (blank and 
drug loaded) were applied onto nude skin of animals of 
II and III groups respectively. A 0.8 % v/v aqueous 
solution of formalin was applied as a standard irritant 
(Group IV).  
The reaction at the site of application was assessed and 
scored according to the following numerical system. A 
score of 0 indicates no erythema and edema formation. A 
score of 1 indicates very slight erythema and edema 
formation (barely perceptible). A score of 2 indicates 
well defined erythema and edema formation (edges of 
area well raised). A score of 3 indicates moderate to 
severe erythema and edema formation (raised 
approx.1mm). A score of 4 indicates severe erythema 
and edema formation (raised more than 1mm and 
extending beyond area of exposure).   
Primary dermal irritation (PDI) score is obtained by 
adding average erythema and average edema scores. 
Primary dermal irritation index (PDII) is obtained by 
adding the PDI scores for 1, 24, 48 and 72 hour scoring 
intervals and dividing by the number of evaluation 
intervals i.e. 4. PDI score for the given tested substance 
is 0 for Non-irritant, 0.1-0.4 for Negligible Irritant, 0.41-
1.9 for Slight Irritant, 2.0-4.9 for Moderate Irritant and 
5.0-8.0 for Severe Irritant. 
53-56
 
VI. Other evaluation instrumental techniques 
a. X-ray diffraction studies  
Diffraction pattern of pure drug, placebo films and drug 
loaded matrix films were scanned over 2θ ranges of 
2
0
and 60
0 
at a rate of 2
0 
per min in 0.02
0
 2θstep size by 
using X-ray diffractometer consisting of a 30KV, 15MA 
generator with a Cu-Kα radiation anode tube was used..  
The X-ray diffraction gives us about the crystal-line and 
amorphous nature of the drug within in the transdermal 
films. The sharp peaks present in diffractogram indicates 
crystalline of the compound which were absent in case of 
amorphous compounds. 
Diffraction pattern of pure drug will show distinctive 
peaks which shows that drug is in crystalline form. For 
the placebo films and drug loaded films no sharp peaks 
were observed indicates that the drug is in amorphous 
state in the drug loaded patches 
57
. 
 
 
Figure 24: Typical X-Ray Diffraction 
b. Scanning electron microscope (SEM) analysis 
For the optimized formulation the external morphology 
of the transdermal patches was analyzed before and after 
in vitro skin permeation using a scanning electron 
microscope (SEM). Films were fixed on aluminium studs 
and coated with gold using a sputter coater SC 502, 
under vacuum [0.1 mm Hg] at 20 kV.  
 
Figure 25: Scanning Electron Microscope 
 
The SEM pictures before in vitro skin permeation 
exhibits the uniform smooth surface which indicates the 
homogeneous dispersion of drug in the transdermal 
films. Uniform distribution of drug in the transdermal 
films is one of the important characteristics and that also 
ensures the uniform reproducible sustained release of 
drug molecules from the films. The SEM pictures after 
the in vitro skin permeation will show the presence of 
pores indicating that the drug was released from the films 
by diffusion 
58
. 
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c. Polariscope examination 
This test is to be performed to examine the drug crystals 
from patch by polariscope. A specific surface area of the 
piece is to be kept on the object slide and observe for the 
drugs crystals to distinguish whether the drug is present 
as crystalline form or amorphous form in the patch 
59,60
. 
VII. Accelerated stability studies 
Stability of a drug has been defined as the stability of a 
particular formulation, in a specific container, to remain 
within its physical, chemical, therapeutic and 
toxicological specifications throughout its shelf life. The 
purpose of stability testing is to provide evidence on how 
the quality of a drug substance or drug product varies 
with time under the influence of a variety of 
environmental factors such as temperature, humidity, 
light, and enables recommended storage conditions, re-
test periods and shelf-lives to be established. The 
International Conference on Harmonization (ICH) 
Guidelines titled “stability testing of New Drug 
substances and products” (QIA) describes the stability 
test requirement for drug registration applications in the 
European Union, Japan and United Stated of America.  
ICH specifies the length of study and storage conditions: 
Long Term testing: 25ºC ± 2ºC / 60% RH ± 5% for 12 
months  
Accelerated Testing: 40ºC ± 2ºC / 75% RH ± 5% for 6 
months 
The selected formulations were packed in amber colored 
bottles, which were tightly plugged with cotton and 
capped with aluminium. They were then stored at 25ºC / 
60% RH, 30ºc / 65% RH, & 40ºC / 75% RH for 3 
months and evaluated for their drug content and other 
physicochemical parameters like thickness, flatness, 
folding endurance, tensile strength, moisture content and 
moisture uptake, drug content as well as drug release. 
The logarithms of percent drug remaining were plotted 
against time in days, which gave almost straight line 
suggesting that drug degradation followed first order 
kinetics. The slope of the straight line for each 
temperature was obtained and the degradation rate 
constant was calculated using the formula given below: 
 
where K is the degradation rate constant 
An Arrhenius plot was drawn by plotting logarithm of K 
values against reciprocals of absolute temperature. The 
value of K at 25°C (K25) was extrapolated from  
the Arrhenius plot and shelf-life of the formulation was 
calculated by substituting the vales of K 25 in the 
following equation 
61,62
: 
 
Where, t0.9 is the time required for 10% degradation of 
the drug and is referred to as the “Shelf-life”of the 
product. 
CONCLUSION 
Transdermal drug delivery systems has been used as safe 
and effective drug delivery system since 1981.Its 
potential role in controlled release is being globally 
exploited by the scientists with high rate of attainment. 
Drug with right mix of physical chemistry and 
pharmacology, is remarkably effective in transdermal 
delivery. Due to large advantages of the TDDS, many 
new researches are going on in the present day to 
incorporate newer drugs via the system. A transdermal 
patch has several basic components like drug reservoirs, 
liners, adherents, permeation enhancers, backing 
laminates, plasticizers and solvents, which play a vital 
role in the release of drug via skin. Transdermal patches 
are divided into various types like matrix, eservoir, 
membrane matrix hybrid; micro reservoir type and drug 
in adhesive type transdermal patches and different 
methods are used to prepare these patches by using basic 
components of TDDS. These are after preparation of 
transdermal patches, evaluated for physicochemical 
studies, in vitro permeation studies, skin irritation 
studies, animal studies, human studies and stability 
studies. All prepared and evaluated transdermal patches 
must receive approval from FDA before sale. Future 
developments of TDDSs will likely focus on the 
increased control of therapeutic regimens and the 
continuing expansion of drugs available for use. 
Transdermal dosage forms may provide clinicians an 
opportunity to offer more therapeutic options to their 
patients to optimize their care. 
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